Development and preclinical characterization of a humanized antibody targeting CXCL12

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4433-4445

  Zhong, Cuiling ^a   Wang, Jianyong ^a   Li, Bing ^a   Xiang, Hong ^a   Ultsch, Mark ^a   Coons, Mary ^a   Wong, Terence ^a   Chiang, Nancy Y ^a   Clark, Suzy ^a   Clark, Robyn ^a   Quintana, Leah ^a   Gribling, Peter ^a   Suto, Eric ^a   Barck, Kai ^a   Corpuz, Racquel ^a   Yao, Jenny ^a   Takkar, Rashi ^a   Lee, Wyne P ^a   Damico Beyer, Lisa A ^a   Carano, Richard D ^a   Adams, Camellia ^a   Kelley, Robert F ^a   Wang, Weiru ^a   Ferrara, Napoleone ^a   more..

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CHIMERIC ANTIBODY; CHIMERIC ANTIBODY 30D8; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 30D8; MONOCLONAL ANTIBODY B20.4.11; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1BETA; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; IC 50; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ARTHRITIS, EXPERIMENTAL; CELL LINE, TUMOR; CHEMOKINE CXCL12; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; EPITOPE MAPPING; FEMALE; HUMANS; MICE; MODELS, MOLECULAR; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN CONFORMATION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882990634     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0943     Document Type: Article

References (51)

1. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007;292:C987-95.
2. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kita-mura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesisinmicelackingtheCXCchemokine PBSF/SDF-1.Nature 1996;382:635-8.
3. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998;393:591-4.
4. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 2007;104:14759-64.
5. Williams DA, Zheng Y, Cancelas JA. Rho GTPases and regulation of hematopoietic stem cell localization. Methods Enzymol 2008;439: 365-93.
6. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009;113:6085-93.
7. Lerman OZ, Greives MR, Singh SP, Thanik VD, Chang CC, Seiser N, et al. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and-independent SDF-1 induction. Blood 2010; 116:3669-76.
8. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-20.
9. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 2010;107: 20009-14.
10. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomaspromote tumor growth and angiogenesis throughelevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48.
11. Stratman AN, Davis MJ, Davis GE. VEGF and FGF prime vascular tube morphogenesis and sprouting directed by hematopoietic stem cell cytokines. Blood 2011;117:3709-19.
12. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62: 7203-6.
13. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007;28:299-307.
14. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4(+) hemangiocytes. Nat Med 2006; 12:557-67.
15. Ferrara N. Role of myeloid cells in vascular endothelial growth factor-independenttumorangiogenesis.CurrOpinHematol 2010;17:219-24.
16. Maksym RB, Tarnowski M, Grymula K, Tarnowska J, Wysoczynski M, Liu R, et al. The role of stromal-derived factor-1-CXCR7 axis in development and cancer. Eur J Pharmacol 2009;625:31-40.
17. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
18. Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 2012;227:404-16.
19. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120:694-705.
20. Baker KN, Rendall MH, Patel A, Boyd P, Hoare M, Freedman RB, et al. Rapid monitoring of recombinant protein products: a comparison of current technologies. Trends Biotechnol 2002;20:149-56.
21. + granulocytes. Proc Natl Acad Sci U S A 2010;107:21248-55.
22. + cells. PLoS ONE 2010;5:e8611.
23. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655-64.
24. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21-34.
25. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007;450: 825-31.
26. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, et al. Crossspecies vegf-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal vegf. J Biol Chem 2006;281:951-61.
27. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res 1999;59:5209-18.
28. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 2008;275:4448-55.
29. Katschke KJ Jr, Helmy KY, Steffek M, Xi H, Yin J, Lee WP, et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J Exp Med 2007;204:1319-25.
30. Barck KH, Lee WP, Diehl LJ, Ross J, Gribling P, Zhang Y, et al. Quantification of cortical bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis. Arthritis Rheum 2004;50: 3377-86.
31. Campa C, Kasman I, Ye W, Lee WP, Fuh G, Ferrara N.Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascu-larization in mice: optimizing methods to quantify vascular changes. Invest Ophthalmol Vis Sci 2008;49:1178-83.
32. Sengupta N, Caballero S, Mames RN, Butler JM, Scott EW, Grant MB. The role of adult bone marrow-derived stem cells in choroidal neo-vascularization. Invest Ophthalmol Vis Sci 2003;44:4908-13.
33. Eter N, Engel DR, Meyer L, Helb HM, Roth F, Maurer J, et al. In vivo visualization of dendritic cells, macrophages, and microglial cells responding to laser-induced damage in the fundus of the eye. Invest Ophthalmol Vis Sci 2008;49:3649-58.
34. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000;20:4106-14.
35. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology 1992; 10:163-7.
36. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992;224:487-99.
37. Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 1970;132:211-50.
38. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997;273:927-48.
39. Tejada ML, Yu L, Dong J, Jung K, Meng G, Peale FV, et al. Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res 2006;12:2676-88.
40. Ryu EK, Kim TG, Kwon TH, Jung ID, Ryu D, Park YM, et al. Crystal structure of recombinant human stromal cell-derived factor-1alpha. Proteins 2007;67:1193-7.
41. Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME, Lolis E. Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem 2007;282:10018-27.
42. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Are-nzana-Seisdedos F, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997;16: 6996-7007.
43. Gravel S, Malouf C, Boulais PE, Berchiche YA, Oishi S, Fujii N, et al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem 2010;285:37939-43.
44. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011;17: 2074-80.
45. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 2012;21:341-53.
46. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167:1676-86.
47. Zhuo W, Jia L, Song N, Lu XA, Ding Y, Wang X, et al. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogen-esis. Clin Cancer Res 2012;18:5387-98.
48. Sloane AJ, Raso V, Dimitrov DS, Xiao X, Deo S, Muljadi N, et al. Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses. Immunol Cell Biol 2005;83:129-43.
49. Baribaud F, Edwards TG, Sharron M, Brelot A, Heveker N, Price K, et al. Antigenically distinct conformations of CXCR4. J Virol 2001;75: 8957-67.
50. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009;75:1240-7.
51. Hotzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012;4:753-60.